The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...
First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...
The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in ...
PHILADELPHIA - In 1982, the surgical cure for prostate cancer was considered worse than the disease. Removing the prostate meant life-threatening bleeding, guaranteed impotence, and a 1 in 4 chance of ...
Among patients with biochemical recurrence after radical prostatectomy, we found previously that postoperative prostate-specific antigen doubling time (PSADT) was associated with risk of prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results